​
QuickLinks-- Click here to rapidly navigate through this document

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.DC 20549

SCHEDULE 14A
(Rule 14a-101)
SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934 (Amendment No.          
Filed by the Registrant ☒
Filed by a Party other than the Registrant ☐
Check the appropriate box:
☒
Preliminary Proxy Statement
​
☐
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

​
☐
Definitive Proxy Statement
​
☐
Definitive Additional Materials
​
☐
Soliciting Material under §240.14a-12
​
JAGUAR HEALTH, INC.
​
Filed by the Registrantý

Filed by a Party other than the Registranto

Check the appropriate box:

ý

Preliminary Proxy Statement

o

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

o

Definitive Proxy Statement

o

Definitive Additional Materials

o

Soliciting Material under §240.14a-12
(Name of Registrant as Specified in Its Charter)


​
JAGUAR HEALTH, INC.
(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

ý

No fee required.

o

Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
(1)Title of each class of securities to which transaction applies:
(2)Aggregate number of securities to which transaction applies:
(3)Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
(4)Proposed maximum aggregate value of transaction:
(5)Total fee paid:

o

Fee paid previously with preliminary materials.

o

Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.



(1)

Amount Previously Paid:
(2)Form, Schedule or Registration Statement No.:
(3)Filing Party:
(4)Date Filed:
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check all boxes that apply):
☒
No fee required.
​
☐
Fee paid previously with preliminary materials.
​
☐
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11.
​

​

[MISSING IMAGE: lg_jaguarhealth-4c.jpg]
LOGO

201 Mission200 Pine Street, Suite 2375,400, San Francisco, CA 9410594104
Tel: 415.371.8300 ·• Fax: 415.371.8311
www.jaguar.health.comhttps://jaguar.health

November [  ], 2017

2022​

Dear Stockholder:

You are cordially invited to attend thea Special Meeting of Stockholders (the "Special Meeting"“Special Meeting”) of Jaguar Health, Inc. (the "Company"“Company”) to be held at 201 Mission200 Pine Street, Suite 2375,400, San Francisco, CA 94105,94104, on Friday, December 1, 2017,January 20, 2023, at 8:0030 a.m., local time.

At the Special Meeting you will be asked to:

    1.
    Approve,to (i) approve the adoption of an amendment to the Company’s Third Amended and Restated Certificate of Incorporation, as amended (the “COI”) to effect a reverse stock split of the Company’s issued and outstanding voting common stock, par value $0.0001 per share (the “Common Stock”) at a ratio not less than 1-for-3 and not greater than 1-for-75, with the exact ratio, if approved and effected at all, to be set within that range at the discretion of the Company’s board of directors and publicly announced by the Company on or before January 22, 2024 without further approval or authorization of the Company’s stockholders (the “Reverse Stock Split”), (ii) approve, pursuant to Nasdaq Listing Rules 5635(b) and (d)Marketplace Rule 5635(d) (“Rule 5635(d)”), the issuance of up to an aggregate of 17,808,144 shares of Jaguarour Common Stock that may be issued(and/or securities convertible into or exercisable for our Common Stock) equal to (i) Chicago Venture Partners, L.P. ("CVP") upon conversion and/20% or redemptionmore of the outstanding balance (including interest thereon), or any portion thereof, of the Convertible Promissory Note, due August 2, 2018, issued by Jaguar to CVP in the original principal amount of $2,155,000 (the "CVP Note"), subject to the terms of the CVP Note, and (ii) Iliad Research and Trading, L.P. ("Iliad"), an affiliate of CVP, upon conversion and/or redemption of the outstanding balance (including interest thereon), or any portion thereof, of the Convertible Promissory Note proposed to be issued by Jaguar to Iliad in the original principal amount of $1,375,000 (the "Iliad Note"), subject to the terms of the Iliad Note, such aggregate shares constituting approximately 19.9% of our outstanding shares of Common Stock assuming conversionoutstanding before the issuance in one or more non-public capital raising transactions, and (iii) approve one or more adjournments of the non-voting common stock (Proposal 1); and

    2.
    Approve a proposal to grant discretionary authority to adjourn the Special Meeting, if necessary, to solicit additional proxies in the event that there are not sufficient votes at the time of the Special Meeting to approve Proposal 1 (Proposal 2)proposals (i) and (ii).

It is important that your shares be represented and voted whether or not you plan to attend the Special Meeting in person. You may votesubmit a proxy to have your shares voted on the Internet, by telephone or by completing and mailing a proxy card. Votingcard or voting instruction form. Submission of proxies over the Internet, by telephone or by written proxymail will ensure your shares are represented at the Special Meeting. If you do attend the Special Meeting, you may, of course, withdraw your proxy should you wish to vote in person. Please read the enclosed information carefully before voting.

Sincerely,
[MISSING IMAGE: sg_lisaaconte-bw.jpg]
Lisa A. Conte
Chief Executive Officer & President

​

Sincerely,



GRAPHIC
Lisa A. Conte
Chief Executive Officer & President

JAGUAR HEALTH, INC.
200 Pine Street
201 Mission Street
Suite 2375400
San Francisco, CA 9410594104

NOTICE OF SPECIAL MEETING OF STOCKHOLDERS
To Be Held Friday, December 1, 2017January 20, 2023

NOTICE HEREBY IS GIVEN that athe Special Meeting of Stockholders (the "Special Meeting"“Special Meeting”) of Jaguar Health, Inc. (the "Company"“Company”) will be held at 201 Mission200 Pine Street, Suite 2375,400, San Francisco, CA 94105,94104, on Friday, December 1, 2017,January 20, 2023, at 8:0030 a.m., local time, for the following purposes:

1.
Approve,   Approving an amendment to the Company’s Third Amended and Restated Certificate of Incorporation, as amended (the “COI”) to effect a reverse stock split of the Company’s issued and outstanding voting common stock, par value $0.0001 per share (the “Common Stock”) at a ratio not less than 1-for-3 and not greater than 1-for-75, with the exact ratio, if approved and effected at all, to be set within that range at the discretion of the Company’s board of directors and publicly announced by the Company on or before January 22, 2024 without further approval or authorization of the Company’s stockholders (the “Reverse Stock Split”) (Proposal 1);
2.   Approving, pursuant to Nasdaq Listing Rules 5635(b) and (d)Marketplace Rule 5635(d) (“Rule 5635(d)”), the issuance of up to an aggregate of 17,808,144 shares of Jaguarour Common Stock that may be issued(and/or securities convertible into or exercisable for our Common Stock) equal to (i) Chicago Venture Partners, L.P. ("CVP") upon conversion and/20% or redemptionmore of the outstanding balance (including interest thereon), or any portion thereof, of the Convertible Promissory Note, due August 2, 2018, issued by Jaguar to CVP in the original principal amount of $2,155,000 (the "CVP Note"), subject to the terms of the CVP Note, and (ii) Iliad Research and Trading, L.P. ("Iliad"), an affiliate of CVP, upon conversion and/or redemption of the outstanding balance (including interest thereon), or any portion thereof, of the Convertible Promissory Note proposed to be issued by Jaguar to Iliad in the original principal amount of $1,375,000 (the "Iliad Note"), subject to the terms of the Iliad Note, such aggregate shares constituting approximately 19.9% of our outstanding shares of Common Stock assuming conversion ofoutstanding before the non-voting common stockissuance in one or more non-public capital raising transactions (Proposal 1)2); and

2.
Approve
3.   Approving a proposal to grant discretionary authority to adjournapprove one or more adjournments of the Special Meeting, if necessary, to solicit additional proxies in the event that there are not sufficient votes at the time of the Special Meeting to approve ProposalProposals 1 and 2 (Proposal 2)3).

        In addition, stockholders may be asked to consider and vote upon such other business as may properly come before the Special Meeting or any adjournment or postponement. The Board of Directors is not aware of any other business to be presented to a vote of the stockholders at the Special Meeting.

Information relating to the above matters is set forth in the attached Proxy Statement. Stockholders of record at the close of business on November 13, 201722, 2022 are entitled to receive notice of and to vote at the SpeicalSpecial Meeting and any adjournment or postponement thereof. This Notice
By Order of Special Meetingthe Board of Stockholders and Proxy Statement and Proxy Card are being sent to stockholders beginning on or about Directors.
[MISSING IMAGE: sg_lisaaconte-bw.jpg]
Lisa A. Conte
Chief Executive Officer & President
San Francisco, California
November [  ], 2017.

2022
Information relating to the above matters is set forth in the attached Proxy Statement. Stockholders of record at the close of business on November 22, 2022 are entitled to receive notice of and to vote at the Special Meeting and any adjournment or postponement thereof. If you have questions concerning the proposals in the Proxy Statement, would like additional copies of the Proxy Statement or need help in voting your shares of Common Stock, please contact our proxy solicitor Georgeson LLC at 866-821-0284.
​​
Important Notice Regarding the Availability of Proxy Materials for the Stockholder Meeting to be Held on January 20, 2023. The proxy materials are available at
https://jaguarhealth.gcs-web.com/financial-information/annual-reports
​By Order of the Board of Directors,



GRAPHIC
Lisa A. Conte
Chief Executive Officer & President​

San Francisco, California


November [    ], 2017

Important Notice Regarding the Availability of Proxy Materials for the Stockholder Meeting

​

to be Held on Friday, December 1, 2017. The proxy materials are available at
[http://phx.corporate-ir.net/phoenix.zhtml?c=253723&p=irol-irhome.]

PLEASE CAREFULLY READ THE ATTACHED PROXY STATEMENT. EVEN IF YOU EXPECT TO ATTEND THE SPECIAL MEETING, PLEASE PROMPTLY COMPLETE, EXECUTE, DATE AND RETURN THE ENCLOSED PROXY CARD OR VOTING INSTRUCTION FORM IN THE ACCOMPANYING POSTAGE-PAID ENVELOPE. NO POSTAGE IS NECESSARY IF MAILED IN THE UNITED STATES. YOU MAY ALSO VOTESUBMIT PROXIES TO HAVE YOUR SHARES VOTED ELECTRONICALLY VIA THE INTERNET OR BY TELEPHONE BY FOLLOWING THE INSTRUCTIONS ON THE ENCLOSED PROXY CARD.CARD OR VOTING INSTRUCTION FORM. IF YOU VOTESUBMITTED A PROXY BY INTERNET OR TELEPHONE, THEN YOU NEED NOT RETURN A WRITTEN PROXY CARD OR VOTING INSTRUCTION FORM BY MAIL. STOCKHOLDERS WHO ATTEND THE SPECIAL MEETING MAY REVOKE THEIR PROXIES AND VOTE IN PERSON IF THEY SO DESIRE.DESIRE (AS DESCRIBED BELOW).

JAGUAR HEALTH, INC.
200 Pine Street
201 Mission Street
Suite 2375400
San Francisco, CA 9410594104

PRELIMINARY

PROXY STATEMENT—SUBJECT TO COMPLETION
STATEMENT
FOR THEA SPECIAL MEETING OF STOCKHOLDERS
To Be Held Friday, December 1, 2017January 20, 2023


GENERAL INFORMATION ABOUT THE SPECIAL MEETING

We are furnishing this Proxy Statement to our stockholders in connection with the solicitation of proxies by our Boardboard of Directorsdirectors to be voted at thea Special Meeting of Stockholders (the “Special Meeting”) and at any adjournment or postponement thereof. The Special Meeting will be held at 201 Mission200 Pine Street, Suite 2375,400, San Francisco, CA 94105,94104, on Friday, December 1, 2017,January 20, 2023, at 8:0030 a.m., local time.

When used in this Proxy Statement, the terms the "Company," "we," "us," "our"“Company,” “we,” “us,” “our” and "Jaguar"“Jaguar” refer to Jaguar Health, Inc.

The Securities and Exchange Commission (“SEC”) rules require us to deliver our proxy materials by mail to all of our stockholders of record as of November 22, 2022 (the “Record Date”). Our proxy materials include the Notice of Special Meeting of Stockholders, this Proxy Statement and the form of proxy card or voting instruction form, and we will mail these proxy materials to stockholders entitled to vote at the meeting on or about November 22, 2022. Pursuant to rules adopted by the Securities and Exchange Commission ("SEC"),SEC, the Company is also providing access to its proxy materials over the Internet. All stockholders will have the ability to access the proxy materials at [http:https://investors.jaguarhealth.com/phoenix.zhtml?c=253723&p=ir ol-reportsannual].

jaguarhealth.gcs-web.com/financial-information/annual-reports.

The date on which the Special Meeting of Stockholders, this Proxy Statement, and the form of proxy card or voting instruction card,form are first being sent or given to stockholders is on or about November [    ], 2017.

December 5, 2022.


GENERAL INFORMATION ABOUT VOTING

Record Date

As of November 13, 2017,22, 2022, the record date for the Special Meeting (the “Record Date”), [           ] shares of our Commonvoting common stock, par value $0.0001 per share (the “Common Stock”) and 10 shares of our Series F Preferred Stock, par value $0.0001 per share (the “Series F Preferred Stock), were issued and outstanding. Only holders of record of our Common Stock or Series F Preferred Stock as of the close of business on the record dateRecord Date are entitled to notice of, and to vote at, the Special Meeting or at any adjournment or postponement thereof. A list of such holders will be open to the examination of any stockholder for any purpose germane to the meeting at Jaguar Health, Inc., 201 Mission200 Pine Street, Suite 2375,400, San Francisco, CA 9410594104 for a period of ten (10) days prior to the Special Meeting. The list of stockholders will also be available for such examination at the Special Meeting. In addition, as of November 13, 2017,22, 2022, there were [           ] shares of our non-voting common stock were outstanding, but these shares will not have anyno voting rights in connection with respect to any of the proposals being considered at the Special Meeting. Each share of non-voting

1
​

common stock is convertible into one-three thousand one hundred fiftieth (1/3,150th) of a share of Common Stock at the election of the holder thereof anytime on or after April 1, 2018 or automatically upon transfer to anyone that is not Nantucket Investments Limited or an affiliated investment fund. thereof.
The use of the capitalized term "Common Stock"“Common Stock” in this Proxy


Statement and related materials refers only to Jaguar'sthe Company’s voting Common Stockcommon stock and does not include Jaguar'sthe Company’s convertible non-voting common stock.

Voting, Quorum and Revocability of Proxies

Each share of our Common Stock entitles the holder of record thereof to one vote. Each share of Series F Preferred Stock entitles the holder of record thereof to 6,000,000,000 votes as provided in the Certificate of Designation of Preferences, Rights and Limitations of Series F Preferred Stock (the “Certificate of Designation”); provided, that, such shares of Series F Preferred Stock are only entitled to vote on Proposal 1, and any votes cast by holders of the Series F Preferred Stock are required to be voted in the same proportion as shares of Common Stock are voted on Proposal 1 (excluding any shares of Common Stock that affirmatively abstain or are otherwise not voted). As an example, if the holders of 50.5% of the outstanding Common Stock voted at the Special Meeting are voted for Proposal 1, then 50.5% of the votes cast by the holders of the Series F Preferred Stock shall be cast for the Proposal 1. No other securities are entitled to be voted at the Special Meeting. Each stockholder holding Common Stock or Series F Preferred Stock may vote in person or by proxyproxy. Holders of record of shares of Common Stock have the right to vote on all matters that properly comebrought before the Special Meeting and any adjournment or postponement thereof.thereof (except as otherwise described below). Holders of record of shares of Series F Preferred Stock have the right to vote only on Proposal 1. Holders of Common Stock and Series F Preferred Stock will vote on Proposal 1 together as a single class.
Stockholders have no right to cumulative voting as to any matter. The presence, in person or represented by proxy, of stockholdersboth (i) holders of one third (1/3) in voting power of the capital stock of the Company outstanding on the Record Date and entitled to vote a majorityat the Special Meeting and (ii) holders of one third (1/3) of the shares of Common Stockcapital stock of the Company outstanding on the record dateRecord Date and entitled to vote at the Special Meeting (including one third (1/3) of the total number of shares of Common Stock) will constitute a quorum for purposes of voting at the Special Meeting. Properly executed proxies marked "ABSTAIN"“ABSTAIN,” as well as broker non-votes, will be counted as "present"“present” for purposes of determining the existence of a quorum. If a quorum should not be present, either the Special Meetingchairperson of the meeting or a majority in voting power of the stockholders present in person or by proxy and entitled to vote on the adjournment may be adjournedadjourn such meeting from time to time until a quorum is obtained.

Our Boardboard of Directors (the "Board")directors is soliciting the enclosed proxyproxies for use in connection with the Special Meeting and any postponement or adjournment thereof. If the enclosedyou submit your proxy is voted via the Internet or by telephone or execute and return the proxy card is executed and returned, theor voting instruction form accompanying this Proxy Statement, your shares represented by it will be voted as directedyou direct on all matters properly coming before the Special Meeting for a vote. For each proposal,Proposals 1, 2 and 3, you may vote "FOR," "AGAINST"“FOR” or "ABSTAIN". Returning“AGAINST” or you may “ABSTAIN.”
If your completedshares are registered directly in your name with our transfer agent, American Stock Transfer & Trust Company, LLC (the “Transfer Agent”), you are considered, with respect to those shares, the stockholder of record. As the stockholder of record, you have the right to grant your proxy directly to the Company or to vote your shares in person at the Special Meeting. If you hold your shares in a stock brokerage account or through a bank or other financial intermediary, you are considered the beneficial owner of shares held in street name. Your bank, broker or other financial intermediary is considered, with respect to those shares, the stockholder of record. As the beneficial owner, you have the right to direct your bank, broker or other financial intermediary on how to vote your shares, but because you are not the stockholder of record, you may not vote these shares in person at the Special Meeting unless you obtain a signed proxy from your bank, broker or other financial intermediary, as the record holder, giving you the right to vote the shares. As a beneficial owner, you are, however, welcome to attend the Special Meeting in person provided that you present proof of beneficial ownership as of the Record Date, such as an account statement or similar evidence of ownership, along with a form of photo identification.
Even if you plan to attend the Special Meeting, we recommend that you also submit your proxy as described in the proxy card or voting oninstruction form, so that your vote will be counted if you later decide

2
​

not to attend the Internet or by telephoneSpecial Meeting. Submitting your proxy now will not prevent you from voting your shares in person by written ballot at the Special Meeting shouldif you be present and desire to do so. so, as your proxy is revocable at your option.
You may revoke your proxy by (a) delivering to the Secretary of the Company at or before the Special Meeting a written notice of revocation bearing a later date than the proxy, (b) duly executing a subsequent proxy relating to the same shares of Common Stock and delivering it to the Secretary of the Company at or before the Special Meeting, or (c) attending the Special Meeting and voting in person (although attendance at the Special Meeting will not in and of itself constitute revocation of a proxy). Any written notice revoking a proxy should be delivered at or prior to the Special Meeting to: Jaguar Health, Inc., 201 Mission200 Pine Street, Suite 2375,400, San Francisco, CA 94105,94104, Attention: KarenJonathan S. Wright.Wolin. Beneficial owners of our Common Stock who are not holders of record and wish to revokechange their proxyvoting direction should contact their bank, brokerage firm or other custodian, nominee or fiduciary to inquire about how to revoke their proxy.

make that change.

The shares represented by all valid proxies received will be voted in the manner specified on the proxies.specified. Where specific choices are not indicated on a valid proxy validly executed and delivered by a holder of Common Stock, the shares represented by such proxies receivedproxy will be voted: (i) “FOR” Proposal 1, which is the approval of the amendment to the Company’s Third Amended and Restated Certificate of Incorporation, as amended (the “COI”) to effect a reverse stock split of the Company’s issued and outstanding Common Stock at a ratio of not less than 1-for-3 and not greater than 1-for-75, with the exact ratio, if approved and effected at all, to be set within that range at the discretion of the Company’s board of directors and publicly announced by the Company on or before January 22, 2024 without further approval or authorization of the Company’s stockholders (the “Reverse Stock Split”) (provided that, in the case of a proxy validly executed and delivered by a holder of Series F Preferred Stock, such proxy will be voted "FOR"in the same proportion as shares of Common Stock are voted on Proposal 1); (ii) “FOR” Proposal 2 which is the approval, pursuant to Nasdaq Marketplace Rule 5635(d) (“Rule 5635(d)”), of the issuance of our Common Stock (and/or securities convertible into or exercisable for our Common Stock) equal to 20% or more of the Common Stock outstanding before the issuance in one or more non-public capital raising transactions; and (ii) “FOR” Proposal 3 which is the approval of one or more adjournments of the Special Meeting, if necessary, to solicit additional proxies in the event that there are not sufficient votes at the time of the Special Meeting to approve Proposals 1 and 2.

We will bear all expenses of this solicitation, including the cost of preparing and mailing this Proxy Statement. We have retained Georgeson LLC to solicit proxies for a base fee of $6,500 plus reimbursement of reasonable out-of-pocket expenses. In addition to solicitation by use of the mail, proxies may be solicited by telephone, facsimile or personally by our directors, officers and employees, who will receive no extra compensation for their services. We will reimburse banks, brokerage firms and other custodians, nominees and fiduciaries for reasonable expenses incurred by them in sending proxy soliciting materials to beneficial owners of shares of Common Stock.

Broker Voting

Brokers holding shares of record in "street name"“street name” for a client have the discretionary authority to vote on some matters (routine matters) if they do not receive instructions from the client regarding how the client wants the shares voted at least 10 days before the date of the Special Meeting.meeting; provided the proxy materials are transmitted to the client at least 15 days before the meeting. There are also some matters (non-routine matters) with respect to which brokers do not have discretionary authority to vote (non-routine matters) if they do not receive timely instructions from the client. When a broker does not have discretion to vote on a particular matter and the client has not given timely instructions on how the broker should vote, a broker non-vote results.


        Proposals 1 and 2 are considered "non-routine" matters. Therefore, if you hold your shares in street name and do not give your Any broker specific voting instructions with respect to Proposals 1 and/or 2, your sharesnon-vote will not be voted, resulting in broker non-votes. Broker non-votes also will not be counted as present at the Special Meeting for purposes of determining a quorum, atbut will be treated as not entitled to vote with respect to non-routine matters.

The proposal to approve the Special Meeting.

Required Vote

Proposal 1

        In voting with regardamendment to the COI to effect the Reverse Stock Split (Proposal 1) and the proposal to approve pursuant to Nasdaq Listing Rules 5635(b) and (d), the issuanceone or more adjournments of up to an aggregate of 17,808,144 shares of Jaguar Common Stock that may be issued to (i) Chicago Venture Partners, L.P. ("CVP") upon conversion and/or redemption of the outstanding balance (including interest thereon), or any portion thereof, of the Convertible Promissory Note, due August 2, 2018, issued by Jaguar to CVP in the original principal amount of $2,155,000 (the "CVP Note"), subject to the terms of the CVP Note, and (ii) Iliad Research and Trading, L.P. ("Iliad"), an affiliate of CVP, upon conversion and/or redemption of the outstanding balance (including interest thereon), or any portion thereof, of the Convertible Promissory Note proposed to be issued by Jaguar to Iliad in the original principal amount of $1,375,000 (the "Iliad Note"), subject to the terms of the Iliad Note, such aggregate shares constituting approximately 19.9% of our outstanding shares of Common Stock assuming conversion of the non-voting common stock, you may vote in favor of the proposal, vote against the proposal or abstain from voting.

        The vote required to approve Proposal 1 is governed by Delaware law, Nasdaq Listing Rules, our Second Amended and Restated Certificate of Incorporation and our Amended and Restated Bylaws and is the affirmative vote of the holders of a majority of the shares represented and entitled to vote at the Special Meeting, provided a quorum is present. As a result, abstentions will be considered in determining whether a quorum is present and the number of votes required to obtain the necessary majority vote and therefore will have the same legal effect as voting against Proposal 1.

Proposal 2

        In voting with regard to the proposal to grant discretionary authority to adjourn the Special Meeting, if necessary, to solicit additional proxies in the event that there are not sufficient votes at the time of the Special Meeting to approve Proposals 1 and 2 (Proposal 3) are considered routine matters and brokers will be permitted to vote in their discretion on such matters on behalf of clients who have not furnished voting instructions at least 10 days before the date of the Special Meeting. In contrast, the proposal to approve, pursuant to Nasdaq Marketplace


3
​

Rule 5635(d) (“Rule 5635(d)”), the issuance of our Common Stock (and/or securities convertible into or exercisable for our Common Stock) equal to 20% or more of the Common Stock outstanding before the issuance in one or more non-public capital raising transactions (Proposal 2) is not considered a “routine” matter and brokers do not have discretionary authority to vote on behalf of clients on such matters.
Required Vote
Proposal 1 — Adoption of the Amendment to the COI to effect the Reverse Stock Split
With respect to the proposal to approve the Amendment to the COI to effect the Reverse Stock Split, you may vote in favor of the proposal, vote against the proposal or abstain from voting. The vote required to approve Proposal 1 is governed by Delaware law, our COI and our Amended and Restated Bylaws, as amended (the “Bylaws”) and is the affirmative vote of the holders of a majority of the voting power of the Common Stock and the Series F Preferred Stock of the Company outstanding as of the Record Date and entitled to vote. As a result, abstentions will be considered in determining whether a quorum is present but will have the same effect as a vote against Proposal 1.
Proposal 2 —  Issuance of Shares of Common Stock in a Private Placement for Purposes of Nasdaq Listing Rule 5635(d)
With respect to the proposal to approve, pursuant to Nasdaq Marketplace Rule 5635(d) (“Rule 5635(d)”), the issuance of shares of the Common Stock (and/or securities convertible into or exercisable for our Common Stock) equal to 20% or more of our Common Stock outstanding before the issuance in one or more non-public capital raising transactions, you may vote in favor of the proposal, vote against the proposal or abstain from voting. The vote required to approve Proposal 2 is governed by Delaware law, the Nasdaq Listing Rules, our Second Amended and Restated Certificate of IncorporationCOI and our AmendedBylaws and Restatedis the affirmative vote of a majority of the votes cast on such proposal by the shares of Common Stock present in person or represented by proxy at the Special Meeting and entitled to vote, provided a quorum is present. As a result, abstentions and broker non-votes will be considered in determining whether a quorum is present but will have no effect on the vote for Proposal 2.
Proposal 3 — Adjournment
With respect to the proposal to approve one or more adjournments the Special Meeting, if necessary, to solicit additional proxies in the event that there are not sufficient votes at the time of the Special Meeting to approve Proposals 1 and 2, you may vote in favor of the proposal, vote against the proposal or abstain from voting. The vote required to approve Proposal 3 is governed by Delaware law, our COI and our Bylaws and is the affirmative vote of the holders of a majority in voting power of the votes cast affirmatively or negatively (excluding abstentions and broker non-votes) by shares represented and entitled to vote at the Special Meeting,of Common Stock, provided a quorum is present. As a result, abstentions will be considered in determining whether a quorum is present and the number of votes required to obtain the necessary majority vote and thereforebut will have no effect on the same legal effect as voting againstvote for Proposal 2.

3.


NO DISSENTERS'DISSENTERS’ RIGHTS

The corporate action described in this Proxy Statement will not afford to stockholders the opportunity to dissent from the actions described herein and receive an agreed or judicially appraised value for their shares of Common Stock.


4


​

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
The statements in this Proxy Statement that are not historical statements, including statements regarding future capital-raising activities and expected use of proceeds therefrom, our estimates regarding expenses, future revenues, capital requirements, needs for additional financing, our ability to obtain additional financing, our success with regard to any business development initiatives, our ability to recruit or retain key scientific or management personnel or to retain our executive officers, our stock price and ability to meet the continued listing requirements of The Nasdaq Capital Market, and any other statements regarding our future expectations, beliefs, plans, objectives, financial conditions, assumptions or future events or performance that are not historical facts, are forward-looking statements within the meaning of the federal securities laws. These statements are subject to numerous risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from the results expressed or implied by the statements. We describe risks and uncertainties that could cause actual results and events to differ materially in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” section of our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (the “Annual Report”), which was filed on March 11, 2022, as revised or supplemented by our most recent Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2022, which was filed on November 14, 2022.
Any forward-looking statements should be considered in light of such important factors. We undertake no obligation to revise or update publicly any forward-looking statements for any reason. Readers are cautioned not to place undue reliance on any forward-looking statement, which speaks only as of the date on which such statement is made.
All subsequent written and oral forward-looking statements concerning the matters addressed in this Proxy Statement and attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this Proxy Statement.

5
​

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

The following table sets forth information regarding the beneficial ownership of shares of our Common Stock and Series F Preferred Stock as of November 1, 201711, 2022 for:

•

each person known to us to be the beneficial owner of more than 5% of our outstanding shares of Common Stock;
​
•

•
each of our named executive officers;
​
•

•
each of our directors; and
​
•

•
all directors and named executive officers as a group.

​
Information with respect to beneficial ownership has been furnished by each director, executive officer or beneficial owner of more than 5% of our Common Stock. Beneficial ownership is determined in accordance with the rules of the SEC and generally includes voting and investment power with respect to the securities. Except as otherwise provided by footnote, and subject to applicable community property laws, the persons named in the table have sole voting and investment power with respect to all shares of Common Stock shown as beneficially owned by them. The number of shares of Common Stock used to calculate the percentage ownership of each listed person includes the shares of Common Stock underlying options or warrants or convertible securities held by such persons that are currently exercisable or convertible or exercisable or convertible within 60 days of November 1, 2017,11, 2022, but are not treated as outstanding for the purpose of computing the percentage ownership of any other person.

Percentage of beneficial ownership is based on 46,870,262(i) 143,222,568 shares of Common Stock, outstanding as of November 1, 2017. This does not include 42,617,893(ii) 2,014,131 shares of our non-voting common stock that were outstanding as of November 1, 2017 but do not have any voting rights. Each share of non-voting common stock is convertible(convertible into one share639 shares of Commonvoting common stock), and (iii) 10 shares of Series F Preferred Stock at the electionas of the holder thereof anytime on or after April 1, 2018 or automatically upon transfer to anyone that is not Nantucket Investments Limited or an affiliated investment fund.

November 11, 2022.

Except as otherwise set forth below, the address of each beneficial owner listed in the table below is c/o Jaguar Health, Inc., 201 Mission200 Pine Street, Suite 2375,400, San Francisco, California 94105.

94104.
VOTING COMMON STOCK
Name and address of beneficial owner​​
Number
of
Shares
Beneficially
Owned
​​
Percentage
of
Shares
Beneficially
Owned
​
5% Stockholders:​​​​​​​​​​​​​
Streeterville Capital LLC(1)
​​​​9,570,757​​​​​6.7%​​
Josh Mailman(2)
​​​​8,614,138​​​​​6.0%​​
Named executive officers and directors:​​​​​​​​​​​​​
Lisa A. Conte(3)
​​​​598,357​​​​​*​​
Steven R. King, Ph.D.(4)
​​​​186,849​​​​​*​​
Jonathan S. Wolin(5)
​​​​142,517​​​​​*​​
Ian Wendt(6)
​​​​80,971​​​​​*​​
James J. Bochnowski(7)
​​​​365,190​​​​​*​​
Jonathan B. Siegel(8)
​​​​126,410​​​​​*​​
John Micek III(9)
​​​​73,797​​​​​*​​
Anula Jayasuriya(10)
​​​​—​​​​​*​​
All current executive officers and directors as a group (8 persons)(11)
​​​​1,574,091​​​​​1.1%​​
Name and address of beneficial owner
 Number of
Shares
Beneficially
Owned		 Percentage of
Shares
Beneficially
Owned		 

5% Stockholders:

       

Entities affiliated with Kingdon Capital Management L.L.C.(1)

  25,457,532  35.8%

Invesco Ltd. 

  6,297,603  13.4%

Nantucket Investments Limited

  4,884,245  10.4%

Named executive officers and directors:

  
 		  
 		 

James J. Bochnowski(2)

  807,843  1.7%

Lisa A. Conte(3)

  508,882  1.1%

Jiahao Qiu(4)

  9,389  —* 

Zhi Yang, Ph.D.(5)

  1,571,825  3.4%

Folkert W. Kamphuis(6)

  106,952  —* 

Steven R. King, Ph.D.(7)

  167,220  —* 

John Micek III(8)

  57,418  —* 

Ari Azhir, Ph.D.(9)

  32,683  —* 

Karen S. Wright(10)

  60,162  —* 

Roger Waltzman

  0  —* 

All current executive officers and directors as a group (10 persons)(11)

  3,322,375  6.9%
​
*

Less than 1%.
​
(1)
The address for the reporting person is 303 E Wacker Drive, Suite 1040 Chicago, IL 60601.
​
(2)
(1)
Represents (i) 1,291,9864,099,758 shares of Common Stock held by Joshua Mailman, (ii) 4,366,665 shares of
​

6
​

Common Stock held by Joshua Mailman Foundation, and (iii) 158,715 shares of Common Stock held by EJM 2012 Trust. Mr. Mailman has voting and investment power over the shares held by the Joshua Mailman Foundation. Ms. Monica Winsor, Mr. Mailman’s spouse, is the sole trustee of the EJM 2021 Trust and has voting and investment power over the shares held by the EJM 2021 Trust. The address of Mr. Mailman and Ms. Winsor are c/o Citrin Cooperman, 50 Rockefeller Plaza, New York, NY 10020.
(3)
Represents (i) 7,978 shares of Common Stock (ii) 850,002577,879 shares of Common Stock issuable upon exercise of warrants, and (iii) 10,946,312 shares of Common Stock issuable upon conversion of the Kingdon Notes owned by Kingdon Capital Management, L.L.C. and 12,369,232 shares of Common Stock issuable upon payment of interest on the Kingdon Notes in lieu of cash convertible at $0.20 per share.

(2)
Includes (i) 587,576 shares of Common Stock, (ii) 99,058 shares of Common Stock issuableto Ms. Conte under stock options that are exercisable or will become exercisable withinin the 60 days ofsubsequent to November 1, 201711, 2022, and (iii) 121,209Bridge Warrants exercisable into 12,500 shares of Common Stock. The weighted average exercise price of the 577,879 stock options is $13.54.
​
(4)
Represents (i) 2 shares of Common Stock and (ii) 186,847 shares of Common Stock issuable under warrants that are exercisable or will become exercisable within 60 days of November 1, 2017. All securities other than stock options are held by the Bochnowski Family Trust. Mr. Bochnowski is a co-trustee and beneficiary of such trust and shares voting and investment control over such shares with his spouse.

(3)
Represents 11,297 shares of Common Stock, and 497,585 shares of stock issuableto Dr. King under stock options that are exercisable or will become exercisable withinin the 60 days subsequent to November 11, 2022. The weighted average exercise price of November 1, 2017.the 186,847 stock options is $14.06.
​
(5)

(4)
Represents 9,389142,517 shares of Common Stock issuable to Mr. Wolin under stock options that are exercisable or will become exercisable withinin the 60 days subsequent to November 11, 2022. The weighted average exercise price of November 1, 2017.the 142,517 stock options is $4.98.
​
(6)

(5)
Represents 1,571,82580,971 shares of Common Stock beneficially held by BVCF. Dr. Yang is the Chairperson, Founder, Managing Partner and sole shareholder of BVCF and he may be deemedissuable to beneficially own all the shares held by BVCF.

(6)
Represents 106,952 shares of Common Stock issuableMr. Wendt under stock options that are exercisable or will become exercisable withinin the 60 days subsequent to November 11, 2022. The weighted average exercise price of November 1, 2017.the 80,971 stock options is $3.69.
​
(7)

(7)
Represents 6,636(i) 60,682 shares of Common Stock, and 160,584(ii) 111,205 shares of Common Stock issuable to Mr. Bochnowski under stock options that are exercisable or will become exercisable withinin the 60 days subsequent to November 11, 2022, and (iii) Series 1, Series 2, and Bridge Warrants exercisable into 193,303 shares of November 1, 2017.Common Stock. The weighted average exercise price of the 111,205 stock options is $18.93.
​
(8)
(8)
Represents 57,419(i) 4,616 shares of Common Stock, (ii) 108,116 shares of Common Stock issuable to Mr. Siegel under stock options that are exercisable or will become exercisable withinin the 60 days subsequent to November 11, 2022, and (iii) Series 1, Series 2, and Bridge Warrants exercisable into 13,678 shares of November 1, 2017.Common Stock. The weighted average exercise price of the 108,116 stock options is $6.98.
​
(9)

(9)
Represents 32,68373,797 shares of Common Stock issuable to Mr. Micek under stock options that are exercisable or will become exercisable withinin the 60 days subsequent to November 11, 2022. The weighted average exercise price of November 1, 2017.the 73,797 stock options is $15.48.
​
(10)

(10)
Represents 60,162
Dr. Jayasuriya was granted 128,851 restricted stock units under the Company’s 2014 Stock Incentive Plan (“Plan”) on July 2, 2022 contingent upon the Company having sufficient authorized shares of Common Stock issuable under the Plan on or before June 30, 2023. Such restricted stock options that are exercisable orunits will become exercisable within 60 daysvest in full on the one-year anniversary of November 1, 2017.the grant date, subject to Dr. Jayasuriya’s continuous service through such vesting date.
​
(11)

(11)
See footnotes (2) - (10)(3 – 10).
​
SERIES F PREFERRED STOCK​
Name of Beneficial Owner​​
Number of Shares of
Series F Preferred Stock
​​
Percentage
Ownership
​
SynWorld Technologies Corporation(a)
​​​​Ten​​​​​100%​​
​
(a)

The Series F Preferred Stock is held of record by SynWorld Technologies Corporation (“SynWorld”). The principal address of SynWorld is 15 Sunny Rose Crt. Whitby, Ontario L1R 1V8, Canada.
​

7


​


PROPOSAL 1—1 — APPROVAL PURSUANTOF AN AMENDMENT TO NASDAQ LISTING RULES 5635(B)OUR THIRD AMENDED AND (D),RESTATED CERTIFICATE OF INCORPORATION TO EFFECT THE ISSUANCE OF UP TO AN AGGREGATE OF 17,808,144 SHARES OF JAGUAR COMMONREVERSE STOCK TO CHICAGO VENTURE PARTNERS, L.P. AND ILIAD RESEARCH AND TRADING, L.P. UNDER CERTAIN CONVERTIBLE PROMISSORY NOTES
SPLIT

At the Special Meeting, holdersstockholders will be asked to approve an amendment to our COI to effect a reverse stock split of our issued and outstanding Common Stock by a numerical ratio of not less than 1-for-3 and not greater than 1-for-75 with the exact ratio, if approved and effected at all, to be set within that range at the discretion of the Board of Directors and publicly announced by the Company on or before January 22, 2024. The proposed amendment to the COI reflecting the Reverse Stock Split is included in Annex A to this Proxy Statement. By approving this proposal, stockholders would give the Board of Directors the authority, but not the obligation, to effect the Reverse Stock Split and full discretion to approve the ratio at which shares of Common Stock will be reclassified, from and including a ratio of one to three and up to and including a ratio of 1-for-3 to 1-for-75. The ratio (if any) selected by the Board of Directors for the Reverse Stock Split would be publicly disclosed by the Company to the stockholders on or before the date on which the amendment to the COI reflecting the Reverse Stock Split is filed with the Secretary of State of the State of Delaware (the “Delaware Secretary of State”).
We are requesting stockholder approval to effect the Reverse Stock Split at a ratio of not less than 1-for-3 and not more than 1-for-75, with the exact ratio determined by the Board of Directors and publicly announced by the Company on or before January 22, 2024, to provide the Board of Directors with the flexibility to determine the appropriate ratio and timing for the Reverse Stock Split based upon our performance and other market factors. However, the Board of Directors reserves the right to elect not to proceed with the Reverse Stock Split, even if approved, and to abandon the Reverse Stock Split if it determines, in its sole discretion, that the Reverse Stock Split is no longer in the best interests of our stockholders. No further action by the stockholders will be required for the Board of Directors to either implement or abandon the Reverse Stock Split. For the avoidance of doubt, except as otherwise specified herein, all share and dollar amounts set forth in this proxy statement are on a pre-Reverse Stock Split basis.
If the Board of Directors does not effect the Reverse Stock Split on or before January 22, 2024, any authority granted to the Board of Directors by our stockholders pursuant to this Proposal 1 will terminate.
Reasons for the Reverse Stock Split
The Board of Directors has authorized the resolution to seek stockholder approval to effect the Reverse Stock Split with the primary intent of increasing the price of our Common Stock in order to meet The Nasdaq Capital Market’s minimum price per share criteria for continued listing on that exchange. Our Common Stock is publicly traded and listed on The Nasdaq Capital Market under the symbol “JAGX.” The Board of Directors believes that, in addition to increasing the price of our Common Stock, the Reverse Stock Split would also reduce certain of our costs, such as Nasdaq listing fees, and make our Common Stock more attractive to a broader range of institutional and other investors. The combination of lower transaction costs and increased interest from institutional investors and investment funds may ultimately improve the trading liquidity of our Common Stock. Accordingly, we believe that authority granted to the Board of Directors to effect the Reverse Stock Split is in the Company’s and the stockholders’ best interests.
On February 17, 2022, we received a letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying us that we were not in compliance with Nasdaq Listing Rule 5550(a)(2) (the “Rule”), as the minimum bid price for our listed securities was less than $1.00 for the previous 30 consecutive business days. Our Common Stock is listed on The Nasdaq Capital Market, which imposes, among other requirements a minimum bid price requirement.
Under Nasdaq Listing Rule 5810(c)(3)(A), we were granted a 180-calendar day grace period, or until August 16, 2022, to regain compliance with the minimum bid price requirement. The continued listing standard would be met if we could evidence a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days during the 180-calendar day grace period. On August 18, 2022, we received a notification letter from the Staff notifying the Company that it had been granted an additional 180 days, or until February 13, 2023, to regain compliance with the minimum bid price requirement based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on The Nasdaq Capital Market with the exception of the bid price requirement, and the Company’s written notice of its intention to cure the deficiency during the second

8
​

compliance period. In the event we do not regain compliance with the $1.00 bid price requirement by February 13, 2023, Nasdaq will provide written notification that the Company’s securities will be delisted. At that time, we may appeal Nasdaq’s determination to a Hearings Panel with a plan to regain compliance.
In addition to establishing a mechanism for the price of our Common Stock to meet Nasdaq’s minimum bid price requirement, we also believe that the Reverse Stock Split will make our Common Stock more attractive to a broader range of institutional and other investors. It is our understanding that the current market price of our Common Stock may affect its acceptability to certain institutional investors, professional investors and other members of the investing public. It is also our understanding that many brokerage houses and institutional investors have internal policies and practices that either prohibit them from investing in low-priced stocks or tend to discourage individual brokers from recommending low-priced stocks to their customers. In addition, some of those policies and practices may function to make the processing of trades in low-priced stocks economically unattractive to brokers. Conversely, we understand that low-priced stocks attract the interest of short-term traders, which may result in significant volatility due to short sellers of common stock and buy-and-hold decisions of longer investors. Moreover, because brokers’ commissions on low-priced stocks generally represent a higher percentage of the stock price than commissions on higher-priced stocks, the current average price per share of our Common Stock can result in individual stockholders paying transaction costs representing a higher percentage of their total share value than would be the case if the share price were substantially higher. However, some investors may view the Reverse Stock Split negatively because it reduces the number of shares of Common Stock available in the public market.
Reducing the number of outstanding shares of our Common Stock through the Reverse Stock Split is intended, absent other factors, to increase the per share market price of our Common Stock. However, other factors, such as our financial results, market conditions and the market perception of our business may adversely affect the market price of our Common Stock. As a result, there can be no assurance that the Reverse Stock Split, if completed, will result in the intended benefits described above, that the market price of our Common Stock will increase following the Reverse Stock Split, that the market price of our Common Stock will not decrease in the future, or that our Common Stock will achieve a high enough price per share to permit its continued listing by Nasdaq.
Certain Risks Associated with the Reverse Stock Split
In evaluating the proposed Reverse Stock Split, the Board of Directors also took into consideration certain risks associated with reverse stock splits generally, including the negative perception of reverse stock splits held by some investors, analysts and other stock market participants, the fact that the stock price of some companies that have effected reverse stock splits has subsequently declined back to pre-reverse stock split levels, and the risks described below.
There can be askedno assurance that the total market capitalization of our Common Stock (the aggregate value of our Common Stock at the then market price) after the implementation of the Reverse Stock Split will be equal to approveor greater than the issuancetotal market capitalization before the Reverse Stock Split or that the per share market price of upour Common Stock following the Reverse Stock Split will increase in proportion to an aggregatethe reduction in the number of 17,808,144 shares of our Common Stock outstanding before the Reverse Stock Split.
There can be no assurance that the market price per share of our Common Stock after the Reverse Stock Split will remain unchanged or increase in proportion to the reduction in the number of shares of our Common Stock outstanding before the Reverse Stock Split. For example, based on the closing price of our Common Stock on November 10, 2022, of $0.13 per share, if the Board of Directors were to implement the Reverse Stock Split and utilize a ratio of 1-for-40, we cannot assure you that the post-split market price of our Common Stock would be $5.20 (that is, $0.13 multiplied by 40) per share or greater. The market price of our Common Stock may fluctuate and potentially decline after the Reverse Stock Split, such as the decline in the market price of our Common Stock that we experienced after our previous reverse stock splits effectuated on June 1, 2018, June 7, 2019 and September 8, 2021.
Accordingly, the total market capitalization of our Common Stock after the Reverse Stock Split when and if approved and effected may be lower than the total market capitalization before the Reverse Stock

9
​

Split. Moreover, in the future, the market price of our Common Stock following the Reverse Stock Split may not exceed or remain higher than the market price prior to the Reverse Stock Split.
If the Reverse Stock Split is approved and effected, the resulting per-share market price may not attract institutional investors or investment funds and may not satisfy the investing guidelines of such investors and, consequently, the trading liquidity of our Common Stock may not improve.
While the Board of Directors believes that a higher stock price may help generate investor interest, there can be no assurance that the Reverse Stock Split will result in a per-share market price that will attract institutional investors or investment funds or that such share price will satisfy the investing guidelines of institutional investors or investment funds. As a result, the trading liquidity of our Common Stock may not necessarily improve.
A decline in the market price of our Common Stock after the Reverse Stock Split is approved and effected may result in a greater percentage decline than would occur in the absence of the Reverse Stock Split.
If the Reverse Stock Split is approved and effected and the market price of our Common Stock declines, the percentage decline may be greater than would occur in the absence of the Reverse Stock Split. The market price of our Common Stock will, however, also be based upon our performance and other factors, which are unrelated to the number of shares of Common Stock outstanding.
Because the number of authorized shares of our Common Stock will not be reduced proportionately, the reverse stock split will increase the Board of Directors’ ability to issue authorized and unissued shares without further stockholder action.
Because the number of authorized shares of our Common Stock will not be reduced proportionately, the reverse stock split will increase the Board of Directors’ ability to issue authorized and unissued shares without further stockholder action. Without taking into account the impact of the proposed reverse stock split, we already have a substantial number of authorized but unissued shares of stock, the issuance of which would be dilutive to our existing stockholders and may cause a decline in the trading price of our Common Stock. With respect to authorized but unissued and unreserved shares, we could also use such shares to oppose a hostile takeover attempt or delay or prevent changes in control or changes in or removal of management. We have an existing at the market offering agreement with Ladenburg Thalmann & Co. Inc. for an “at the market” equity offering program and are in discussions to conduct an equity financing as described in Proposal 2 to this proxy statement. Other than the foregoing, there are no existing plans, arrangements or understandings relating to the issuance of any of the authorized, but unissued and unreserved shares, whether available as a result of the proposed reverse stock split or otherwise.
Effecting the Reverse Stock Split; Board of Directors’ Discretion to Implement Reverse Stock Split
If approved by stockholders at the Special Meeting and the Board of Directors decides that it is in the best interests of the Company and our stockholders to effect the Reverse Stock Split, the Board of Directors will establish an appropriate ratio for the Reverse Stock Split based on several factors existing at such time, the Company will publicly announce the ratio selected by the Board of Directors and we will subsequently file an amendment to the COI, in the form of the proposed amendment to COI attached in Annex A. The Board of Directors will consider, among other factors, prevailing market conditions, the likely effect of the Reverse Stock Split on the trading price of our Common Stock and on our compliance with applicable Nasdaq listing requirements, and the marketability and liquidity of our Common Stock. The Board of Directors will also determine the appropriate timing for filing the amendment to our COI with the Delaware Secretary of State to effect the Reverse Stock Split. If, for any reason, the Board of Directors deems it advisable, the Board of Directors in its sole discretion may abandon the Reverse Stock Split at any time prior to the effectiveness of the amendment to our COI, without further action by our stockholders. Assuming the Board of Directors determines that it is in the best interests of the Company and our stockholders to proceed with the Reverse Stock Split, the Reverse Stock Split will be effective as of the date and time set forth in the amendment to our COI that is filed with the Delaware Secretary of State (the “Effective Time”).
At the Effective Time, without any further action on the part of the Company or our stockholders, the outstanding shares of Common Stock held by stockholders of record as of the Effective Time will be converted into a lesser number of shares of Common Stock based on the ratio selected by the Board of

10
​

directors and publicly announce by the Company. For example, if the Board of Directors approves a ratio of 1-for-40, a stockholder who holds 400,000 shares of Common Stock as of the Effective Time will hold 10,000 shares of Common Stock following the Reverse Stock Split.
Effect on Outstanding Shares, Options, and Certain Other Securities
If the Reverse Stock Split is approved and effected, the number of shares of our Common Stock owned by each stockholder will be reduced in the same proportion as the reduction in the total number of shares outstanding, such that the percentage of our Common Stock owned by each stockholder will remain unchanged, except for any de minimis change resulting from the treatment of any fractional shares that such stockholder would have received as a result of the Reverse Stock Split. The number of shares of Common Stock that may be issued to (i) CVPreceived upon conversion, and/exercise or redemptionexchange, as the case may be, of outstanding options or other securities convertible into, or exercisable or exchangeable for, shares of our Common Stock, and the exercise or conversion prices for these securities, will also be adjusted in accordance with their terms, as of the outstanding balance (including interest thereon), or any portion thereof,Effective Time.
Effect on Registration and Stock Trading
Our Common Stock is currently registered under Section 12(b) of the CVP Note,Securities Exchange Act of 1934, as amended (the “Exchange Act”), and we are subject to the termsperiodic reporting and other requirements of the CVP Note,Exchange Act. The proposed Reverse Stock Split will not affect the registration of our Common Stock under the Exchange Act. If the Reverse Stock Split is approved and (ii) Iliad upon conversion and/or redemptioneffected, our Common Stock will receive a new CUSIP number.
Mechanics of Reverse Split
If this Proposal 1 is approved by the stockholders at the Special Meeting and the Board of Directors decides that it is in the best interests of the outstanding balance (including interest thereon), or any portion thereof,Company and our stockholders to effect the Reverse Stock Split, our stockholders will be notified of the Iliad Note, subjectratio for the Reverse Stock Split selected by the Board of Directors and that the Reverse Stock Split has been approved and effected. The mechanics of the Reverse Stock Split will differ depending upon whether a stockholder holds its shares of Common Stock in brokerage accounts or “street name” or whether the shares are registered directly in a stockholder’s name and held in book-entry form or certificate form.
•
Our stockholders who hold shares of Common Stock in “street name” through a nominee (such as a bank or broker) will be treated in the same manner as stockholders whose shares are registered in their names, and nominees will be instructed to effect the Reverse Stock Split for their beneficial holders. However, nominees may have different procedures for processing the reverse stock split and stockholders holding shares in “street name” are encouraged to contact their nominees.
​
•
Our registered stockholders may hold some or all of their shares of Common Stock electronically in book-entry form under the direct registration system for securities. These stockholders will not have stock certificates evidencing their ownership of our Common Stock. They are, however, provided with a statement reflecting the number of shares registered in their accounts. Stockholders holding registered shares of our Common Stock in book-entry form need not take any action to receive post-Reverse Stock Split shares as a transaction statement will automatically be sent to the termsstockholder’s address of record indicating the Iliad Note. All per share dollar figures included in this Proposal 1are subject to adjustment for stock splits, stock dividends, reclassifications and other similar recapitalization transactions.

number of shares held.

​
Background•

CVP Note

        On June 29, 2017, prior to

Some of our acquisition of Napo Pharmaceuticals, Inc. through a merger, we entered into a definitive agreement with CVP for the issuance of the CVP Note at a purchase price of $1,700,000. Under the terms of the CVP Note, the noteholder may convert any amount of the outstanding balance of the CVP Note (including interest thereon) intoregistered stockholders hold all their shares of Jaguar common stock atCommon Stock in certificate form or a conversion pricecombination of $1.00 per share at any timecertificate and book-entry form. Stockholders holding shares of Common Stock in certificate form will receive a transmittal letter from the Transfer Agent as soon as practicable after the earlier of (i) December 29, 2017 and (ii) the effective date of the resale registration statement that Jaguar has filed to register the resaleReverse Stock Split. The letter of shares issuable upon conversion of the CVP Note (the "Resale S-3 Effective Date"). In addition, beginning on the earlier of (i) December 29, 2017 and (ii) the Resale S-3 Effective Date, CVPtransmittal will have the right to redeem a portion of the outstanding balance of the CVP Note (including interest thereon) in any amount up to $350,000 per month. If redemption is made prior to December 29, 2017, the redemption must be satisfied in Jaguar stock valued at $1.00 per share. After December 29, 2017, the redemption(s) may be satisfied in cash or stock valued at $1.00 per share, at the election of Jaguar; provided, however, that if Jaguar stock is trading below $1.15 per share, the redemption must be in cash, unless the parties consent to a different conversion price in accordance with the terms of the CVP Note. CVP cannot redeem more than $350,000 per month under the CVP Note. In addition, CVP has the right to purchase 100% of the debt under Jaguar's term loan so long as the purchase includes the full pay-out of funds owed to the lender under the term loan at such time. Pursuant to the terms of the CVP Note, we have granted CVP a springing security interest in substantially all of Jaguar's assets that becomes effective upon the earlier to occur of (1) repayment in full of the term loan owing to Hercules Capital, Inc. or (2) the purchase of the Hercules Capital, Inc term loan by CVP.

Iliad Note

        Our management is in the process of negotiating a definitive agreement with Iliad, an affiliate of CVP (collectively, the "Funds"),contain instructions for the issuancesurrender of the Iliad Note in the original principal amount of $1,375,000 for a purchase price of $1,100,000. Under the terms of the Iliad Note, the noteholder may convert any amount of the outstanding balance of the Iliad Note (including interest thereon) into shares of Jaguar common stock at a conversion price of $0.52 per share at any time commencing six months after the date that Iliad delivers the purchase price of the Iliad Note to Jaguar (the "Iliad Note Purchase Price Date").

        In addition, beginning on the earlier of (i) the effective date of the resale registration statement that Jaguar has agreed to file to register the resale of shares issuable upon conversion of the Iliad Note or (ii) January 31, 2018, Iliad will have the right to redeem a portion of the outstanding balance of the Iliad Note in any amount up to $500,000 per month less the amount of any redemptions by CVP under


the CVP Note during such month. If redemption is made prior to January 31, 2018, the redemption must be satisfied in Jaguar Common Stock valued at $0.52 per share. After January 31, 2018, the redemption(s) may be satisfied in cash or stock, at the election of Jaguar; provided, however, that if Jaguar Common Stock is trading below $0.52 per share, then Jaguar must pay the redemption in cash, unless the parties consent to a different conversion price in accordance with the terms of the Iliad Note.

Stockholder Approval Requirement

        Pursuant to Nasdaq Listing Rule 5635(b), stockholder approval is requiredcertificates received prior to the issuanceEffective Time (the “Old Certificates”) to the Transfer Agent in exchange for new certificates representing the appropriate number of securities whenwhole shares of Common Stock giving effect to the issuanceReverse Stock Split. No new stock certificates will be issued to any stockholder until such stockholder has surrendered all Old Certificates, together with a properly completed and executed Letter of Transmittal, to the Transfer Agent. The stockholders will then receive, at their option, either a new certificate or potential issuancecertificates or book-entry shares representing the number of securities will result in a changewhole shares of control of Jaguar. Nasdaq defines a "change of control" as occurring when,Common Stock into which their pre-Reverse Stock Split shares have been

​

11
​

converted as a result of an issuance, an investor or group would own, or have the rightReverse Stock Split. Until surrendered, we will deem outstanding Old Certificates held by stockholders to acquire 20% or morebe cancelled and to only represent the number of the outstandingwhole shares of common stock orpost-Reverse Stock Split Common Stock to which the voting powerstockholders are entitled. STOCKHOLDERS SHOULD NOT DESTROY ANY STOCK CERTIFICATE(S) AND SHOULD NOT SUBMIT ANY CERTIFICATE(S) UNTIL REQUESTED TO DO SO.
Treatment of a company, and such ownership or voting powerFractional Shares
Stockholders who would beotherwise hold fractional shares because the largest ownership position. The issuancenumber of shares of Common Stock they hold before the Reverse Stock Split is not evenly divisible, based on the Reverse Stock Split ratio approved by our Board of Directors, will be entitled to CVPreceive cash (without interest or deduction) in lieu of such fractional shares from our Transfer Agent, upon receipt by our Transfer Agent of a properly completed and duly executed transmittal letter and, where shares are held in certificated form, the surrender of all old certificate(s), in an amount per share equal to the product obtained by multiplying (a) the closing price per share of our Common Stock on the effective date for the Reverse Stock Split as reported on the Nasdaq Stock Market by (b) the fraction of the share owned by the stockholder, without interest. The ownership of a fractional share interest will not give the holder any voting, dividend or other rights, except to receive the above-described cash payment.
Effect on Authorized but Unissued Shares of Capital Stock
Currently, we are authorized to issue up to a total of 298,000,000 shares of Common Stock, of which [         ] shares were issued and outstanding as of the Record Date, 50,000,000 shares of non-voting common stock, of which [           ] shares were issued and outstanding as of the Record Date ([           ] shares of Common Stock on an as converted basis), and 4,475,074 shares of Preferred Stock, of which [           ] were issued and outstanding as of the Record Date. The Reverse Stock Split, if approved and effected, will not have any effect on the authorized number of shares of our Common Stock, non-voting common stock or Preferred Stock.
Accounting Consequences
The Reverse Stock Split will not affect the par value of our Common Stock per share, which will remain $0.0001 par value per share. As a result, as of the Effective Time, the total of the stated capital attributable to Common Stock and the additional paid-in capital account on our balance sheet will not change due to the Reverse Stock Split. Reported per share net income or loss will be higher because there will be fewer shares of Common Stock outstanding.
No Going Private Transaction
Notwithstanding the decrease in the number of outstanding shares following the implementation of the Reverse Stock Split, the Board of Directors does not intend for this transaction to be the first step in a “going private transaction” within the meaning of Rule 13e-3 of the Exchange Act, and the implementation of the proposed Reverse Stock Split will not cause the Company to go private.
No Dissenters’ Rights
Under the General Corporation Law of the State of Delaware (the “DGCL”), stockholders will not be entitled to dissenters’ rights with respect to the proposed amendment to our COI to effect the Reverse Stock Split, and we do not intend to independently provide stockholders with any such right.
Reservation of Right to Abandon the Amendment to our COI
The Board of Directors reserves the right to abandon the proposed amendment to our COI described in this Proposal 1 without further action by our stockholders at any time before the Effective Time, even if stockholders approve this Proposal 1 at the Special Meeting. By voting in favor of the Reverse Stock Split, stockholders are also expressly authorizing the Board of Directors to determine not to proceed with, and abandon, the Reverse Stock Split if it should so decide.
Material U.S. Federal Income Tax Consequences of the Reverse Stock Split
The following discussion is a summary of the material U.S. federal income tax consequences of the proposed Reverse Stock Split to U.S. Holders (as defined below) of our Common Stock. This discussion is

12
​

based on the Internal Revenue Code of 1986, as amended (the “Code”), U.S. Treasury Regulations promulgated thereunder, judicial decisions, and published rulings and administrative pronouncements of the U.S. Internal Revenue Service (the “IRS”), in each case in effect as of the date of this proxy statement. These authorities may change or be subject to differing interpretations. Any such change or differing interpretation may be applied retroactively in a manner that could adversely affect a U.S. Holder. We have not sought and will not seek any rulings from the IRS regarding the matters discussed below and there can be no assurance the IRS or a court will not take a contrary position to that discussed below regarding the tax consequences of the proposed Reverse Stock Split.
For purposes of this discussion, a “U.S. Holder” is a beneficial owner of our Common Stock that, for U.S. federal income tax purposes, is or is treated as (i) an individual who is a citizen or resident of the United States; (ii) a corporation (or any other entity or arrangement treated as a corporation) created or organized under the laws of the United States, any state thereof, or the District of Columbia; (iii) an estate, the income of which is subject to U.S. federal income tax regardless of its source; or (iv) a trust if (1) its administration is subject to the primary supervision of a court within the United States and all of its substantial decisions are subject to the control of one or more “United States persons” ​(within the meaning of Section 7701(a)(30) of the Code), or (2) it has a valid election in effect under applicable U.S. Treasury regulations to be treated as a United States person.
This discussion is limited to U.S. Holders who hold our Common Stock as a “capital asset” within the meaning of Section 1221 of the Code (generally, property held for investment). This discussion does not address all U.S. federal income tax consequences relevant to the particular circumstances of a U.S. Holder, including the impact of the Medicare contribution tax on net investment income. In addition, it does not address consequences relevant to U.S. Holders that are subject to special rules, including, without limitation, financial institutions, insurance companies, real estate investment trusts, regulated investment companies, grantor trusts, tax-exempt organizations, brokers, dealers or traders in securities, commodities or currencies, stockholders who hold our Common Stock as part of a position in a straddle or as part of a hedging, conversion or integrated transaction for U.S. federal income tax purposes, U.S. Holders that have a functional currency other than the U.S. dollar, or U.S. Holders who actually or constructively own 10% or more of our voting stock.
If a partnership (or other entity treated as a partnership for U.S. federal income tax purposes) is the beneficial owner of our Common Stock, the U.S. federal income tax treatment of a partner in the partnership will generally depend on the status of the partner and the activities of the partnership. Accordingly, partnerships (and other entities treated as partnerships for U.S. federal income tax purposes) holding our Common Stock and the partners in such entities should consult their own tax advisors regarding the U.S. federal income tax consequences of the proposed Reverse Stock Split to them.
In addition, the following discussion does not address the U.S. federal estate and gift tax, alternative minimum tax, or state, local and non-U.S. tax law consequences of the proposed Reverse Stock Split. Furthermore, the following discussion does not address any tax consequences of transactions effectuated before, after or at the same time as the proposed Reverse Stock Split, whether or not they are in connection with the proposed Reverse Stock Split.
Each stockholder should consult his, her or its own tax advisors concerning the particular U.S. federal tax consequences of the Reverse Stock Split, as well as the consequences arising under the laws of any other taxing jurisdiction, including any state, local or foreign income tax consequences.
The proposed Reverse Stock Split is intended to be treated as a “recapitalization” for U.S. federal income tax purposes pursuant to Section 368(a)(1)(E) of the Code. As a result, a U.S. Holder generally should not recognize gain or loss upon the conversion or redemptionproposed Reverse Stock Split for U.S. federal income tax purposes, except with respect to cash received in lieu of fractional shares, as discussed below. A U.S. Holder’s aggregate adjusted tax basis in the shares of our Common Stock received pursuant to the proposed Reverse Stock Split should equal the aggregate adjusted tax basis of the CVP Note, together withshares of our Common Stock exchanged therefor (excluding the issuanceamount of such basis that is allocated to any fractional shares for which the U.S. Holder receives cash). The U.S. Holder’s holding period in the shares of our Common Stock received pursuant to the proposed Reverse Stock Split should include the holding period in the shares of our Common Stock exchanged therefor. U.S. Treasury Regulations provide detailed rules for allocating the tax basis and holding

13
​

period of shares of Common Stock surrendered in a recapitalization to Iliad uponshares received in the conversion or redemptionrecapitalization. U.S. Holders of shares of our Common Stock acquired on different dates and at different prices should consult their tax advisors regarding the allocation of the Iliad Note, could resulttax basis and holding period of such shares.
A U.S. Holder that receives cash in lieu of fractional shares pursuant to the Funds being the largest owner of Jaguar Commonproposed Reverse Stock Split generally should recognize capital gain or loss in an amount greaterequal to the difference, if any, between the amount of cash received and the portion of the U.S. Holder’s aggregate adjusted tax basis in the shares of our Common Stock surrendered that is allocated to such fractional shares. Such capital gain or loss generally should be long term if such pre-reverse split shares were held for more than 20%one year. Long-term capital gains recognized by non-corporate U.S. Holders may be eligible to be taxed at reduced rates. The deductibility of capital losses is subject to limitations.
A U.S. Holder of our Common Stock may be subject to information reporting and backup withholding on cash paid in lieu of a fractional share in connection with the proposed Reverse Stock Split. A U.S. Holder of our Common Stock generally will be subject to backup withholding if such U.S. Holder is not otherwise exempt and such U.S. Holder does not provide its taxpayer identification number in the manner required or otherwise fails to comply with applicable backup withholding tax rules. Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules may be refunded or allowed as a credit against a U.S. Holder’s federal income tax liability, if any, provided the required information is timely furnished to the IRS.
The U.S. federal income tax discussion set forth above does not discuss all aspects of U.S. federal income taxation that may be relevant to a particular stockholder in light of such stockholder’s circumstances and income tax situation. Accordingly, we urge you to consult with your own tax advisor with respect to all of the potential U.S. federal, state, local and foreign tax consequences to you of the Reverse Stock Split.
Consequences if the Reverse Split is Not Approved
In the event that the Reverse Stock Split is not approved, we intend to actively monitor the trading price of our Common Stock on The Nasdaq Capital Market and will consider available options to resolve our non-compliance with the Nasdaq listing rules. We believe that our ability to remain listed on The Nasdaq Capital Market would be significantly and negatively affected if the Reverse Stock Split is not approved. If we are unable to achieve an increase in our stock price and our Common Stock is subsequently delisted, we could experience significant negative impacts including no longer being able to sell shares under our at-the-market program. In addition, if our Common Stock is delisted it may adversely affect our ability to obtain alternative debt or equity financing in order to support Company operations.
Background on our Series F Preferred Stock
On November 10, 2022, we entered into a securities purchase agreement with SynWorld, pursuant to which we issued 10 shares of Series F Preferred Stock to SynWorld for gross proceeds of $100 (the “Preferred Issuance Transaction”). The shares of Series F Preferred Stock have an original issue price of $10 per share. The terms of the Series F Preferred Stock are set forth in a Certificate of Designation of Preferences, Rights and Limitations of Series F Preferred Stock (the “Certificate of Designation”) filed with the State of Delaware and effective on November 10, 2022.
The shares of Series F Preferred Stock do not have any voting rights except with respect to Proposal 1 presented at this Special Meeting and at any adjournments or postponements thereof, or otherwise as required by law or as set forth in the Certificate of Designation. Shares of Series F Preferred Stock are only entitled to vote on Proposal 1, and any votes cast by holders of the Series F Preferred Stock are required to be voted in the same proportions as shares of Common Stock are voted on Proposal 1 (excluding any shares of Common Stock that affirmatively abstain or are otherwise not voted).
Each holder of record of our Series F Preferred Stock is entitled to 6,000,000,000 votes per share of Series F Preferred Stock, or an aggregate of 60,000,000,000 votes for all of the issued and outstanding shares of Jaguar Common Stock.

        Pursuant to Nasdaq Listing Rule 5635(d), stockholder approval is also required prior to the issuance of securities in connection with a transaction other than a public offering involving: (i) the sale, issuance or potential issuance by us of common stock (or securities convertible into or exercisable for common stock) at a price less than the greater of book or market value which together with sales by our officers, directors or substantial stockholders equals 20% or more of common stock or 20% or moreSeries F Preferred Stock as of the voting power outstanding beforeRecord Date; provided, that, such shares of Series F Preferred Stock are only entitled to vote on Proposal 1, and any votes cast by the issuance; or (ii)holders of Series F Preferred Stock are required to be voted in the sale, issuance or potential issuance by us of common stock (or securities convertible into or exercisable common stock) equal to 20% or more of the common stock or 20% or more of the voting power outstanding before the issuance for less than the greater of book or market value of the stock. The issuance ofsame proportion as shares of Common Stock to CVP upon the conversion or redemption of the CVP Note, together with the issuance ofare voted on Proposal 1 (excluding


14
​

any shares of Common Stock to Iliad uponthat affirmatively abstain or are otherwise not voted). As an example, if the conversion or redemptionholders of 50.5% of the Iliad Note, could result inoutstanding Common Stock voted at the issuanceSpecial Meeting are voted for Proposal 1, then 50.5% of the votes cast by the holders of the Series F Preferred Stock shall be cast for Proposal 1.
The shares of CommonSeries F Preferred Stock to the Funds that represents more than 20% of our Common Stock or 20% of the voting power outstanding prior to the issuance of the CVP Note.

        On June 29, 2017, there were 17,482,501 shares of our Common Stock issued and outstanding. Accordingly, our issuance of more than 3,496,500 shares under the CVP Note and Iliad Note requires the approval of our stockholders under Nasdaq Listing Rules 5635(b) and (d), assuming that the CVP Note and Iliad Note transactions are integrated for purposes of the Nasdaq rules. As of November 1, 2017, there were 46,870,262 shares of our Common Stock issued and outstanding. This does not include 42,617,893 shares of our non-voting common stock that were outstanding as of Novemberthe Record Date. Within three business days following the approval or rejection of Proposal 1 2017.

        We are, therefore, seeking stockholder approvalby our stockholders, the Company will redeem all of the issued and outstanding shares of Series F Preferred Stock for the issuance of up to an aggregate of 17,808,144 shares of our Common Stock that may be issued to (i) CVP upon conversion and/or redemption of the outstanding balance (including interest thereon), or any portion thereof, of the CVP Note, subject to the terms of the CVP Note, and (ii) Iliad upon conversion and/or redemption of the outstanding balance (including interest thereon), or any portion thereof, of the Iliad Note, subject to the terms of the Iliad Note, such aggregate shares constituting approximately 19.9% of our outstanding shares of Common Stock assuming conversion of the non-voting common stock.

$100.

Required Vote of Stockholders

        To

The vote required to approve the issuance of up to an aggregate of 17,808,144 shares of Jaguar Common Stock that may be issued to the Funds upon conversion and/or redemption of the CVP Note and the Iliad Note,


Proposal 1 is the affirmative vote of the holders of a majority of the voting power of the Common Stock and Series F Preferred Stock of the Company outstanding as of the Record Date and entitled to vote, voting together as a single class.

Effect of Abstentions
Because approval of Proposal 1 is based on the affirmative vote of a majority of the voting power of the Common Stock and Series F Preferred Stock of the Company, abstentions will be counted for purposes of establishing quorum, and if a quorum is present, will have the same effect as a vote “AGAINST” this proposal with respect to any abstaining shares.
However, you should be aware that the Series F Preferred Stock has 6,000,000,000 votes per share on Proposal 1 and votes of the shares of JaguarSeries F Preferred Stock, when cast, are required to be voted in the same proportion as the aggregate shares of Common Stock presentthat are voted on Proposal 1 (excluding any shares of Common Stock that affirmatively abstain or are otherwise not voted). Although a failure to vote or affirmatively abstaining will therefore have the same effect of voting your shares of Common Stock against Proposal 1, it will not impact how the Series F Preferred Stock is voted because a failure to vote or an abstention is disregarded when determining how the Series F Preferred Stock will be voted on Proposal 1. Only shares of Common Stock affirmatively voted against Proposal 1 will have the effect of causing the percentage of the votes cast by the Series F Preferred Stock to be voted against Proposal 1 to increase proportionately. Accordingly, if you prefer that Proposal 1 not be approved, you should cast your vote against Proposal 1 rather than abstaining or failing to vote.
The Board of Directors unanimously recommends that the stockholders vote “FOR” Proposal 1 to effect a reverse stock split at a ratio of not less than 1-for-3 and not greater than 1-for-75, with the exact ratio, if approved and effected at all, to be set within that range at the discretion of the Board of Directors and publicly announced by the Company on or before January 22, 2024, without further approval or authorization of our stockholders.

15
​

PROPOSAL 2 — APPROVAL OF THE ISSUANCE OF SHARES OF COMMON STOCK IN PRIVATE PLACEMENT
At the Special Meeting, stockholders will be asked to approve, pursuant to Nasdaq Marketplace Rule 5635(d) (“Rule 5635(d)”), the issuance of our Common Stock (and/or securities convertible into or exercisable for our Common Stock) equal to 20% or more of the Common Stock outstanding before the issuance in one or more non-public capital raising transactions.
Stockholder Approval Requirement
Our Common Stock is currently listed on the Nasdaq Capital Market and, as such, we are subject to Nasdaq Marketplace Rules. Nasdaq Marketplace Rule 5635(d) (“Rule 5635(d)”) requires us to obtain stockholder approval prior to the issuance of our Common Stock in connection with certain non-public offerings involving the sale, issuance or potential issuance by the Company of Common Stock (and/or securities convertible into or exercisable for common stock) equal to 20% or more of the Common Stock outstanding before the issuance. Shares of our Common Stock issuable upon the exercise or conversion of warrants, options, debt instruments or other equity securities issued or granted in such non-public offerings will be considered shares issued in such a transaction in determining whether the 20% limit has been reached, except in certain circumstances.
We may seek to raise additional capital to implement our business strategy and enhance our overall capitalization. We have not determined the particular terms for such prospective offerings. Because we may seek additional capital that triggers the requirements of Rule 5635(d), we are seeking stockholder approval now, so that we will be able to move quickly to take full advantage of any opportunities that may develop in the equity markets.
We hereby submit this Proposal 2 to our stockholders for their approval of the potential issuance of shares of our Common Stock, or securities convertible into our Common Stock, in one or more non-public capital-raising transactions, or offerings, subject to the following limitations:
•
the aggregate number of shares issued in the offerings will not exceed 160,000,000 shares of our Common Stock (including for this purpose shares of Common Stock issuable upon conversion of preferred stock), subject to adjustment for stock splits, reverse stock splits, stock dividends and similar transactions effected prior to the offerings;
​
•
the purchase price of the securities offered (which may consist of shares of convertible preferred stock) will be no less than $0.11 per share of Common Stock;
​
•
the investors in any offering will be prohibited from disposing of the offered securities for a period of at least four months following the closing of such offering (the “Lock-Up Period”);
​
•
as conditions to any such offering, (A) the Company would agree (i) to suspend the issuance of shares of Common Stock pursuant to its At The Market Offering Agreement, dated December 10, 2021, with Ladenburg Thalmann & Co. Inc. as agent (the “ATM”) and (ii) not to issue any shares of Common Stock to certain debt holders in exchange transactions pursuant to Section 3(a)(9) of the Securities Act until the end of the Lock-Up Period and (B) certain holders of the Company’s existing debt would agree to defer any interest payments due until the end of the Lock-Up Period;
​
•
such offerings may also include cash compensation to the placement agent in an amount not to exceed in the aggregate 9% of the gross proceeds from such offerings and warrant coverage to the placement agent not to exceed 13% (there will be no warrants issued to investors);
​
•
such offerings will occur, if at all, on or before the date that is three months following the date the Private Placement Proposal is approved by stockholders; and
​
•
such other terms as our Board of Directors shall deem to be in the best interests of the Company and its stockholders, not inconsistent with the foregoing.
​
Potential Effects of this Proposal
The issuance of shares of our Common Stock, or other securities convertible into shares of our Common Stock, in accordance with any offerings would dilute, and thereby reduce, each existing

16
​

stockholder’s proportionate ownership in our Common Stock. The stockholders do not have preemptive rights to subscribe to additional shares that may be issued by the Company in order to maintain their proportionate ownership of the Common Stock.
The issuance of shares of Common Stock, or securities convertible into our Common Stock, in one or more non-public offerings could have an anti-takeover effect. Such issuance could dilute the voting power of a person seeking control of the Company, thereby deterring or rendering more difficult a merger, tender offer, proxy contest or an extraordinary corporate transaction opposed by the Company.
Our Board of Directors has not yet determined the terms and conditions of any offerings. As a result, the level of potential dilution cannot be determined at this time, but as discussed above, we may not issue more than 160,000,000 shares of Common Stock in the aggregate pursuant to the authority requested from stockholders under this proposal (subject to adjustment for any reverse stock split, and including for this purpose shares issuable upon conversion or exercise of preferred stock, options, warrants, convertible debt or other securities convertible into or exercisable for Common Stock). It is possible that if we conduct a non-public stock offering, some of the shares we sell could be purchased by one or more investors who could acquire a large block of our Common Stock. This would concentrate voting power in the hands of a few stockholders who could exercise greater influence on our operations or the outcome of matters put to a vote of stockholders in the future.
We cannot determine what the actual net proceeds of the offerings will be until they are completed, but as discussed above, the aggregate dollar amount of the non-public offerings will be no more than $15.0 million.
If all or part of the offerings is completed, we expect the net proceeds will be used for working capital and general corporate purposes. Assuming that we raise the full $15.0 million in such offerings, we believe we will have sufficient capital to complete our on-going Phase 3 study being conducted to potentially expand the indication of Mytesi to include cancer therapy related diarrhea. We currently have no definitive arrangements or understandings regarding any specific transaction with investors, so we cannot predict whether we will be successful should we seek to raise capital through any offerings.
Required Vote of Stockholders
The affirmative vote of a majority of the votes cast for this proposal, in person or by remote communication, if applicable, or represented by proxy at the Special Meeting, voting together as a single class and entitled to vote, is required. Although failurerequired to submit a proxyapprove the issuance of securities in one or votemore non-public offerings, as required by and in person at the special meeting, or a failure to provide your broker, nominee, fiduciary or other custodian, as applicable,accordance with instructions on how to vote your shares will not affect the outcome of the vote on this proposal, the failure to submit a proxy or vote in person at the special meeting will make it more difficult to meet the requirement under Jaguar's bylaws that the holders of a majority of the Jaguar capital stock issued and outstanding and entitled to vote at the Special Meeting be present in person or by proxy to constitute a quorum at the special meeting.

Nasdaq Marketplace Rule 5635(d)

The Board of Directors unanimously recommends that the stockholders vote "FOR"“FOR” Proposal No. 12 to authorizeapprove the issuance pursuant toof securities in one or more non-public offerings, as required by and in accordance with Nasdaq Listing Rules 5635(b) and (d), of up to an aggregate of 17,808,144 shares of our Common Stock to the Funds under the CVP Note and the Iliad Note.

Marketplace Rule 5635(d).

17
​

PROPOSAL 2—GRANT OF DISCRETIONARY AUTHORITY3 — APPROVAL TO ADJOURN THE SPECIAL MEETING IF NECESSARY TO SOLICIT ADDITIONAL PROXIES

Although it is not expected, the Special Meeting may be adjourned for the purpose of soliciting additional proxies. Any such adjournment of the Special Meeting may be made without notice, other than by the announcement made at the Special Meeting, by approval of the holders of a majority of the outstanding shares of our Common Stock, present in person or represented by proxy and entitled to vote at the Special Meeting, whether or not a quorum exists. We are soliciting proxies to grant discretionary authority to the chairpersonapprove one or more adjournments of the Special Meeting to adjourn the Special Meeting, if necessary, for the purpose of soliciting additional proxies in favor of Proposal 1.Proposals 1 and 2. The chairperson will have the discretion to decide whether or not to use the authority granted to such person pursuant tosubmit this Proposal 23 to adjourn the Special Meeting.

stockholders.

Required Vote of Stockholders

To approve the grantadjournment of discretionary authority to the chairperson of the Special Meeting to adjourn the Special Meeting, if necessary, for the purpose of soliciting additional proxies in favor of ProposalProposals 1 and 2, the affirmative vote of the holders of a majority in voting power of the votes cast affirmatively or negatively (excluding abstentions and broker non-votes) by shares of Jaguar Common Stock, present in person or by remote communication, if applicable, or represented by proxy at the Special Meeting, voting together asprovided a single class and entitled to vote,quorum is present, is required. Although failure to submit a proxy or vote in person at the special meeting,Special Meeting, or a failure to provide your broker, nominee, fiduciary or other custodian, as applicable, with instructions on how to vote your shares will not affect the outcome of the vote on this proposal, the failure to submit a proxy or vote in person at the special meetingSpecial Meeting will make it more difficult to meet the requirement under Jaguar's bylawsthe Bylaws and the COI that the holders of a majorityone third (1/3) in voting power of the Jaguarour capital stock issued and outstanding and entitled to vote at the Special Meeting and holders of one third (1/3) of the shares of capital stock issued and outstanding and entitled to vote at the Special Meeting (including one third (1/3) of the total number of shares of Common Stock) be present in person or by proxy to constitute a quorum at the special meeting.

Special Meeting.

The Board of Directors unanimously recommends that the stockholders vote "FOR"“FOR” Proposal No. 2 to grant discretionary authority3 to adjourn the Special Meeting, if necessary, to solicit additional proxies in favor of Proposal 1.

Proposals 1 and 2.

18


​


STOCKHOLDER PROPOSALS FOR 20182023 ANNUAL MEETING

In accordance with SEC Rule 14a-8, in order for stockholder proposals intended to be presented at the 20182023 Annual Meeting of Stockholders to be eligible for inclusion in our proxy statement and the form of proxy for such meeting, they must be received by us at our executive offices in San Francisco, California, before December 15, 2017.January 19, 2023. The Board of Directors has not determined the date of the 20182023 Annual Meeting of the Company'sCompany’s Stockholders, but does not currently anticipate that the date will be changed by more than 30 calendar days from the date of this year's annual meeting.

the 2022 Annual Meeting of Stockholders.

Stockholder proposals (including recommendations of nominees for election to the Board of Directors) intended to be presented at the 2023 Annual Meeting of Stockholders, other than a stockholder proposal submitted pursuant to SEC Rule 14a-8, must be received in writing at our principal executive office no earlier than February 10, 2023 and no later March 12, 2023, in accordance with our bylaws. If the date of the 2023 Annual Meeting of Stockholders is scheduled for a date more than 30 days before or more than 60 days after June 10, 2023, then such proposals must be received no earlier than the 120th day prior to the 2023 Annual Meeting and not later than the 90th day prior to 2023 Annual Meeting or, if later, the 10th day following the day on which public disclosure of the date of the 2023 Annual Meeting of Stockholders is first made, as set forth in our Bylaws.

AVAILABILITY OF ANNUAL REPORT TO STOCKHOLDERS AND REPORT ON FORM 10-K

Copies of our Annual Report on Form 10-K for the fiscal year ended December 31, 2016 as filed with the Securities and Exchange Commission (exclusive of exhibits and documents incorporated by reference), may be obtained for free by directing written requests to: Jaguar Health, Inc., Attention: KarenJonathan S. Wright, 201 MissionWolin, 200 Pine Street, Suite 2375,400, San Francisco, CA 9410594104 (415.371.8300 phone). Copies of exhibits and basic documents filed with the Annual Report on Form 10-K or referenced therein will be furnished to stockholders upon written request and payment of a nominal fee in connection with the furnishing of such documents. You may also obtain the Annual Report on Form 10-K over the Internet at the SEC'sSEC’s website, www.sec.gov, or at [http:https://phx.corporate-ir.net/phoenix.zhtml?c=253723&p=irol-sec].

jaguarhealth.gcs-web.com/financial-information/annual-reports.


LIST OF THE COMPANY'SCOMPANY’S STOCKHOLDERS

A list of our stockholders as of November 13, 2017,22, 2022, the record date for the Special Meeting,Record Date, will be available for inspection at our corporate headquarters during normal business hours during the 10-day period prior to the Special Meeting. The list of stockholders will also be available for such examination at the Special Meeting.


DELIVERY OF PROXY MATERIALS TO HOUSEHOLDS

Unless contrary instructions are received, we may send a single copy of the Proxy Statement and Notice of Special Meeting to any household at which two or more stockholders reside if we believe the stockholders are members of the same family. Each stockholder in the household will continue to receive a separate proxy card. This process is known as "householding"“householding” and helps reduce the volume of duplicate information received at a single household, which reduces costs and expenses borne by us.

If you would like to receive a separate set of our annual disclosure documents this year or in future years, follow the instructions described below and we will deliver promptly a separate set. Similarly, if you share an address with another stockholder and the two of you would like to receive only a single set of our annual disclosure documents, follow the instructions below:

1.

If your shares are registered in your own name, please contact our transfer agent by writing to them at Computershare Investor Services, PO Box 30170, College Station, Texas 77842-3170American Stock Transfer & Trust Company, LLC, 6201 15th Ave., Brooklyn, NY 11219 (Attn: Jaguar Health, Inc. Representative), calling 1-800-937-5449, or calling 1-800-962-4284.emailing help@astfinancial.com.
​

19
​

2.

If a bank, broker or other nominee holds your shares, please contact your bank, broker or other nominee directly.

​
By Order of the Board of Directors.
[MISSING IMAGE: sg_lisaaconte-bw.jpg]
Lisa A. Conte
Chief Executive Officer & President
OTHER MATTERS THAT MAY COME BEFORESan Francisco, California
November [  ], 2022

20
​

ANNEX A​
CERTIFICATE OF SEVENTH AMENDMENT TO THE SPECIAL MEETING
THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF

        Our
JAGUAR HEALTH, INC.

Jaguar Health, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies that:
1.   The name of the Corporation is Jaguar Health, Inc. The date of filing of the Corporation’s original Certificate of Incorporation with the Secretary of State of the State of Delaware (the “the Delaware Secretary of State”) was June 6, 2013, under the name Jaguar Animal Health, Inc.
2.   This Certificate of Seventh Amendment to the Third Amended and Restated Certificate of Incorporation was duly authorized and adopted by the Corporation’s Board of Directors knowsand stockholders in accordance with Section 242 of no matters other than those referredthe General Corporation Law of the State of Delaware and amends the provisions of the Company’s Third Amended and Restated Certificate of Incorporation.
3.   The amendment to the existing Third Amended and Restated Certificate of Incorporation being effected hereby is as follows:
a.   Add the following paragraph at the end of Section IV.A. as a new Section IV.A.9:
“9. Fourth Reverse Stock Split. Upon this Amendment to the Third Restated Certificate becoming effective pursuant to the DGCL (the “Seventh Amendment Effective Time”), each three (3) to seventy-five (75) shares of Common Stock issued and outstanding immediately prior to the Seventh Amendment Effective Time shall automatically be reclassified and combined into one (1) validly issued, fully paid and non-assessable share of Common Stock, the exact ratio within the foregoing range to be determined by the Board of Directors prior to the Seventh Amendment Effective Time and publicly announced by the Corporation, without any further action by the Corporation or the holder thereof (the “Fourth Reverse Stock Split”). No fractional shares shall be issued in connection with the Fourth Reverse Stock Split. Stockholders who otherwise would be entitled to receive fractional shares of Common Stock shall be entitled to receive cash (without interest or deduction) from the Corporation’s transfer agent in lieu of such fractional share interests upon the submission of a transmission letter by a stockholder holding the shares in book-entry form and, where shares are held in certificated form, upon the surrender of the stockholder’s Old Certificates (as defined below), in an amount equal to the product obtained by multiplying (a) the closing price per share of the Common Stock as reported on the Nasdaq Capital Market as of the date of the Seventh Amendment Effective Time, by (b) the fraction of one share owned by the stockholder. Each certificate that immediately prior to the Seventh Amendment Effective Time represented shares of Common Stock (“Old Certificates”), shall thereafter represent that number of shares of Common Stock into which the shares of Common Stock represented by the Old Certificate shall have been combined, subject to the elimination of fractional share interests as described above.”
4.   This Certificate of Seventh Amendment to the Third Amended and Restated Certificate of Incorporation shall be effective at 12:01 a.m., Eastern Time, on January [   ], 2023.
****

A-1
​

IN WITNESS WHEREOF, Jaguar Health, Inc. has caused this Certificate of Seventh Amendment to the Third Amended and Restated Certificate of Incorporation to be signed by [                 ], its [           ], this [•] day of [•], 2023.
JAGUAR HEALTH, INC.
A Delaware corporation
By:
​
​
Name:
Title:

A-2
​
[MISSING IMAGE: tm2229955d1-px_01proxybw.jpg]
SPECIAL MEETING OF STOCKHOLDERS OF JAGUAR HEALTH, INC. January 20, 2023 PROXY VOTING INSTRUCTIONS INTERNET - Access “www.voteproxy.com” and follow the on-screen instructions or scan the QR code with your smartphone. Have your proxy card available when you access the web page. TELEPHONE - Call toll-free 1-800-PROXIES (1-800-776-9437) in the accompanying Notice of Special Meeting of Stockholders whichUnited States or 1-718-921-8500 from foreign countries from any touch-tone telephone and follow the instructions. Have your proxy card available when you call. Vote online/phone until 11:59 PM EST the day before the meeting. MAIL - Sign, date and mail your proxy card in the envelope provided as soon as possible. IN PERSON - You may properly come beforevote your shares in person by attending the Special Meeting. However,GO GREEN - e-Consent makes it easy to go paperless. With e-Consent, you can quickly access your proxy material, statements and other eligible documents online, while reducing costs, clutter and paper waste. Enroll today via www.astfinancial.com to enjoy online access. COMPANY NUMBER ACCOUNT NUMBER NOTICE OF INTERNET AVAILABILITY OF PROXY MATERIALS: The Notice of Meeting, proxy statement and proxy card are available at https://jaguarhealth.gcs-web.com/financial-information/annual-reports Please detach along perforated line and mail in the envelope provided IF you are not voting via telephone or the Internet. 00030000300300001000 4 012023 THE BOARD OF DIRECTORS RECOMMENDS A VOTE "FOR" PROPOSALS 1, 2 AND 3. PLEASE SIGN, DATE AND RETURN PROMPTLY IN THE ENCLOSED ENVELOPE. PLEASE MARK YOUR VOTE IN BLUE OR BLACK INK AS SHOWN HERE x FOR AGAINST ABSTAIN 1. Approve the adoption of an amendment to the Company’s Third Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split of the Company’s issued and outstanding voting common stock, par value $0.0001 per share (the “Common Stock”) at a ratio not less than 1-for-3 and not greater than 1-for-75, with the exact ratio, if any other matter shouldapproved and effected at all, to be properly presentedset within that range at the discretion of the Company’s board of directors and publicly announced by the Company on or before January 22, 2024 without further approval or authorization of the Company’s stockholders. 2. Approve, pursuant to Nasdaq Marketplace Rule 5635(d), the issuance of Common Stock (and/or securities convertible into or exercisable for consideration and voting atour Common Stock) equal to 20% or more of the Common Stock outstanding before the issuance in one or more non-public capital raising transactions. 3. Approve one or more adjournments of the Special Meeting, or any adjournments or postponements thereof, it isif necessary, to solicit additional proxies in the intentionevent that there are not sufficient votes at the time of the persons namedSpecial Meeting to approve Proposals 1 and 2. This proxy when properly executed will be voted as


proxies directed herein by the undersigned stockholder. MARK “X” HERE IF YOU PLAN TO ATTEND THE MEETING. To change the address on your account, please check the box at right and indicate your new address in the address space above. Please note that changes to the registered name(s) on the enclosed formaccount may not be submitted via this method. Signature of proxy card to voteStockholder Date: Signature of Stockholder Date: Note: Please sign exactly as your name or names appear on this Proxy. When shares are held jointly, each holder should sign. When signing as executor, administrator, attorney, trustee or guardian, please give full title as such. If the shares representedsigner is a corporation, please sign full corporate name by all valid proxy cardsduly authorized officer, giving full title as such. If signer is a partnership, please sign in accordance with their judgment of what is in the best interest of the Company.

partnership name by authorized person. □□□
By Order of the Board of Directors.



GRAPHIC
Lisa A. Conte
Chief Executive Officer & President



QuickLinks

GENERAL INFORMATION ABOUT THE SPECIAL MEETING
GENERAL INFORMATION ABOUT VOTING
NO DISSENTERS' RIGHTS
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
PROPOSAL 1—APPROVAL, PURSUANT TO NASDAQ LISTING RULES 5635(B) AND (D), OF THE ISSUANCE OF UP TO AN AGGREGATE OF 17,808,144 SHARES OF JAGUAR COMMON STOCK TO CHICAGO VENTURE PARTNERS, L.P. AND ILIAD RESEARCH AND TRADING, L.P. UNDER CERTAIN CONVERTIBLE PROMISSORY NOTES
PROPOSAL 2—GRANT OF DISCRETIONARY AUTHORITY TO ADJOURN THE SPECIAL MEETING IF NECESSARY TO SOLICIT ADDITIONAL PROXIES
STOCKHOLDER PROPOSALS FOR 2018 ANNUAL MEETING
AVAILABILITY OF ANNUAL REPORT TO STOCKHOLDERS AND REPORT ON FORM 10-K
LIST OF THE COMPANY'S STOCKHOLDERS
DELIVERY OF PROXY MATERIALS TO HOUSEHOLDS
OTHER MATTERS THAT MAY COME BEFORE THE SPECIAL MEETING